E3 ubiquitin ligase RNF183 is a novel regulator in inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 10, Issue 6, 2016, Pages 713-725

  Yu, Qiao ^a   Zhang, Shenghong ^a   Chao, Kang ^a   Feng, Rui ^a   Wang, Huiling ^a   Li, Manying ^a   Chen, Baili ^a   He, Yao ^a   Zeng, Zhirong ^a   Chen, Minhu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Inflammatory bowel disease; Intestinal inflammation; MicroRNA 7; NF B; RNF183; TNF Infliximab

Indexed keywords

AZATHIOPRINE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MICRORNA; MICRORNA 7; RNF183 PROTEIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR INHIBITOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; I KAPPA B KINASE ALPHA; MIRN7 MICRORNA, HUMAN; MIRN7 MICRORNA, MOUSE; RNF183 PROTEIN, HUMAN; RNF183 PROTEIN, MOUSE; TRINITROBENZENESULFONIC ACID; UBIQUITIN PROTEIN LIGASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASE REPORT; COLITIS; CONTROLLED STUDY; CROHN DISEASE; DOWN REGULATION; ENTERITIS; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INFLAMMATORY BOWEL DISEASE; INTESTINAL TISSUE; INTESTINE EPITHELIUM CELL; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRINITROBENZENE SULFONIC ACID-INDUCED COLITIS; UBIQUITINATION; UPREGULATION; WESTERN BLOTTING; ADOLESCENT; AGED; ANIMAL; BAGG ALBINO MOUSE; CASE CONTROL STUDY; CHEMICALLY INDUCED; COLON; DNA MICROARRAY; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; BIOMARKERS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; COLITIS; COLON; CROHN DISEASE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; MICRORNAS; MIDDLE AGED; NF-KAPPA B; NF-KAPPAB INHIBITOR ALPHA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRINITROBENZENESULFONIC ACID; UBIQUITIN-PROTEIN LIGASES; UP-REGULATION; YOUNG ADULT;

EID: 84985032696     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw023     Document Type: Article

References (60)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
2. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011;474:298-306.
3. Ventham NT, Kennedy NA, Nimmo ER, et al. Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics. Gastroenterology 2013;145:293-308.
4. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 2006;17:1807-19.
5. Baumeister W, Walz J, Zuhl F, et al. The proteasome: paradigm of a selfcompartmentalizing protease. Cell 1998;92:367-80.
6. Motta JP, Magne L, Descamps D, et al. Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis. Gastroenterology 2011;140:1272-82.
7. Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007;117:636-47.
8. Nakamura N. The Role of the Transmembrane RING Finger Proteins in Cellular and Organelle Function. Membranes [Basel] 2011;1:354-93.
9. Heuze ML, Lamsoul I, Moog-Lutz C, et al. Ubiquitin-mediated proteasomal degradation in normal and malignant hematopoiesis. Blood Cells Mol Dis 2008;40:200-10.
10. Hadina S, Wohlford-Lenane CL, Thorne PS. Comparison of in vivo bioluminescence imaging and lavage biomarkers to assess pulmonary inflammation. Toxicology 2012;291:133-8.
11. Deng CX. Roles of BRCA1 in centrosome duplication. Oncogene 2002;21:6222-7.
12. Salghetti SE, Caudy AA, Chenoweth JG, et al. Regulation of transcriptional activation domain function by ubiquitin. Science 2001;293:1651-3.
13. Starita LM, Parvin JD. The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr Opin Cell Biol 2003;15:345-50.
14. Zhong B, Zhang Y, Tan B, et al. The E3 ubiquitin ligase RNF5 targets virus-induced signaling adaptor for ubiquitination and degradation. J Immunol 2010;184:6249-55.
15. Shembade N, Parvatiyar K, Harhaj NS, et al. The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-kappaB signalling. EMBO J 2009;28:513-22.
16. Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor alphaproducing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-66.
17. Magnani M, Crinelli R, Bianchi M, et al. The ubiquitin-dependent proteolytic system and other potential targets for the modulation of nuclear factor-kB [NF-kB]. Curr Drug Targets 2000;1:387-99.
18. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19[Suppl A]:5A-36A.
19. Eugene C. The second European evidence-based consensus on the diagnosis and management of Crohn's disease. Clin Res Hepatol Gastroenterol 2011;35:340-3.
20. Loftus EJ, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1998;114:1161-8.
21. Macarini L, Stoppino LP, Centola A, et al. Assessment of activity of Crohn's disease of the ileum and large bowel: proposal for a new multiparameter MR enterography score. Radiol Med 2013;118:181-95.
22. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif [GETAID]. Gut 1989;30:983-9.
23. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012;6:965-90.
24. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.
25. Jansen MJ, Hendriks T, Hermsen R, et al. A monoclonal antibody against tumour necrosis factor-alpha improves survival in experimental multiple organ dysfunction syndrome. Cytokine 1998;10:904-10.
26. Yu Q, Zhu S, Zhou R, et al. Effects of sinomenine on the expression of microRNA-155 in 2,4,6-trinitrobenzenesulfonic acid-induced colitis in mice. PLoS One 2013;8:e73757.
27. Wu X, Sun L, Zha W, et al. HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells. Gastroenterology 2010;138:197-209.
28. Zhao XD, Lu YY, Guo H, et al. MicroRNA-7/NF-kappaB signaling regulatory feedback circuit regulates gastric carcinogenesis. J Cell Biol 2015;210:613-27.
29. Wang J, Wu M, Wen J, et al. MicroRNA-155 induction by Mycobacterium bovis BCG enhances ROS production through targeting SHIP1. Mol Immunol 2014;62:29-36.
30. Zhang S, Zhong B, Chen M, et al. Epigenetic reprogramming reverses the malignant epigenotype of the MMP/TIMP axis genes in tumor cells. Int J Cancer 2014;134:1583-94.
31. Moynagh PN. The NF-kappaB pathway. J Cell Sci 2005;118:4589-92.
32. Sato F, Tsuchiya S, Meltzer SJ, et al. MicroRNAs and epigenetics. FEBS J 2011;278:1598-609.
33. Kong D, Piao YS, Yamashita S, et al. Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells. Oncogene 2012;31:3949-60.
34. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34.
35. Lorick KL, Jensen JP, Fang S, et al. RING fingers mediate ubiquitin-conjugating enzyme [E2]-dependent ubiquitination. Proc Natl Acad Sci U S A 1999;96:11364-9.
36. Ardley HC. Ring finger ubiquitin protein ligases and their implication to the pathogenesis of human diseases. Curr Pharm Des 2009;15:3697-715.
37. Joazeiro CA, Weissman AM. RING finger proteins: mediators of ubiquitin ligase activity. Cell 2000;102:549-52.
38. Deng J, Liang H, Ying G, et al. Methylation of CpG sites in RNF180 DNA promoter prediction poor survival of gastric cancer. Oncotarget 2014;5:3173-83.
39. Cleynen I, Vazeille E, Artieda M, et al. Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease. Gut 2014;63:1265-74.
40. Beaudoin M, Goyette P, Boucher G, et al. Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS Genet 2013;9:e1003723.
41. Marjoram L, Alvers A, Deerhake ME, et al. Epigenetic control of intestinal barrier function and inflammation in zebrafish. Proc Natl Acad Sci U S A 2015;112:2770-5.
42. Colas E, Perez C, Cabrera S, et al. Molecular markers of endometrial carcinoma detected in uterine aspirates. Int J Cancer 2011;129:2435-44.
43. Tomioka N, Morita K, Kobayashi N, et al. Array comparative genomic hybridization analysis revealed four genomic prognostic biomarkers for primary gastric cancers. Cancer Genet Cytogenet 2010;201:6-14.
44. Chen J, Chen ZJ. Regulation of NF-kappaB by ubiquitination. Curr Opin Immunol 2013;25:4-12.
45. Yamamoto Y, Gaynor RB. Role of the NF-kappaB pathway in the pathogenesis of human disease states. Curr Mol Med 2001;1:287-96.
46. Tokunaga F, Sakata S, Saeki Y, et al. Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat Cell Biol 2009;11:123-32.
47. Shembade N, Harhaj NS, Liebl DJ, et al. Essential role for TAX1BP1 in the termination of TNF-alpha-, IL-1-and LPS-mediated NF-kappaB and JNK signaling. EMBO J 2007;26:3910-22.
48. Chapman CG, Pekow J. The emerging role of miRNAs in inflammatory bowel disease: a review. Therap Adv Gastroenterol 2015;8:4-22.
49. Pekow JR, Kwon JH. MicroRNAs in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:187-93.
50. Fang Y, Xue JL, Shen Q, et al. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology 2012;55:1852-62.
51. Zhang N, Li X, Wu CW, et al. microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis. Oncogene 2013;32:5078-88.
52. Kalinowski FC, Brown RA, Ganda C, et al. microRNA-7: a tumor suppressor miRNA with therapeutic potential. Int J Biochem Cell Biol 2014;54:312-7.
53. Kefas B, Godlewski J, Comeau L, et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 2008;68:3566-72.
54. Webster RJ, Giles KM, Price KJ, et al. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 2009;284:5731-41.
55. Reddy SD, Ohshiro K, Rayala SK, et al. MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res 2008;68:8195-200.
56. Nguyen HT, Dalmasso G, Yan Y, et al. MicroRNA-7 modulates CD98 expression during intestinal epithelial cell differentiation. J Biol Chem 2010;285:1479-89.
57. Liang G, Malmuthuge N, McFadden TB, et al. Potential regulatory role of microRNAs in the development of bovine gastrointestinal tract during early life. PLoS One 2014;9:e92592.
58. Oshima H, Oshima M. The role of PGE2-associated inflammatory responses in gastric cancer development. Semin Immunopathol 2013;35:139-50.
59. Olsen T, Goll R, Cui G, et al. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. Cytokine 2009;46:222-7.
60. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.